Merck (MRK) starts phase 2b/3 trial evaluating Tiespectus for the treatment of neovascular age-related macular degeneration

Merck's initiation of a phase 2b/3 trial for Tiespectus could bolster its position in the competitive ophthalmology market, particularly for neovascular age-related macular degeneration.

Newsquawk StaffPublished 2 Apr 2026, 11:11 UTCOn the live feed at 10:51 UTC — 4 more headlines followed before this page went public

Newsquawk headlinesUTC

10:58

[MARKET UPDATE]: After reports IRGC targeted US-linked metals facilities in the Gulf, saw oil rise to session highs, as did the Dollar, to the detriment of G10 peers

10:53

IRGC say they targeted US-linked steel and aluminium facilities in Gulf states, state media reports; adds that the strikes were a warning and that if Iranian industries are hit again, Tehran’s next response will be more painful

10:51

Merck (MRK) starts phase 2b/3 trial evaluating Tiespectus for the treatment of neovascular age-related macular degeneration

10:50

Russia is likely to experience oil production cuts following drone attacks, Reuters reports citing sources

10:46

The European Commission has approved Merck's (MRK) KEYTRUDA plus Paclitaxel with or without Bevacizumab for the treatment of adults with PD-L1 platinum-resistant recurrent ovarian cancer

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

Context

This development may attract interest from both investors and analysts, as successful trial outcomes could lead to significant revenue potential and influence future sales projections. The market response will likely hinge on investor sentiment toward biopharma trials and the broader healthcare landscape in Europe and the U.S.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/8 Sept · 11:48 UTC

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations.

Market, after we published+1.0%

EQUITIES/7 Sept · 10:54 UTC

Saudi Aramco Jizan oil facilities were reportedly hit in new strikes, the FT reports citing sources; hit on Monday, damage is being assessed.

Equity indices, after we published−0.1%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.